A newly expanded recall of Mylan NV’s epinephrine auto-injector EpiPen shows that even a company that has long prided itself on supply chain quality is not immune from a high-profile recall due to manufacturing issues.
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Pricing controversy around the product got the CEO hauled before Congress; now what began as an overseas recall of one lot made by a Pfizer subsidiary threatens to besmirch Mylan’s once golden supply chain quality record.
